U.S. market Closed. Opens in 6 hours 1 minute

RNAZ | TransCode Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue516.75K98.61K42.47KN/AN/A
Gross Profit-516.75K-98.61K-42.47KN/AN/A
Operating Expenses18.90M17.59M5.87M726.60K456.87K
Selling, General & Admin6.64M8.43M3.40M442.14K230.56K
Research & Development12.26M10.23M2.75M284.46K226.31K
Other Operating Expenses0-1.08M-278.33KN/AN/A
Operating Income-19.42M-18.67M-6.15M-726.60K-456.87K
Other Expenses / Income872.42K1.10M-692.26K-1.62M-150.35K
Before Tax Income-18.55M-17.56M-6.84M-2.34M-607.21K
Income Tax Expenses4.0017.56M95.07K394.44K156.93K
Net Income-18.55M-35.13M-6.94M-2.74M-764.14K
Interest Expenses-55.90M17.56M95.07K394.57K156.97K
Basic Shares Outstanding179.00K16.00K10.53K7.98K6.41K
Diluted Shares Outstanding179.01K16.22K10.53K7.98K6.41K
EBITDA-18.90M-17.47M-5.83M-726.47K-456.83K
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-74.45MN/A-6.75M-1.95M-450.25K
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙